title: [Dysmetabolic hyperferritinemia: a new target for treatment?].
abstract: Dysmetabolic hyperferritinemia is currently the most frequent cause of elevated ferritin levels in the general population. Whether dysmetabolic hyperferritinemia is a cause or an effect of insulin resistance is still a matter of debate. Still, several findings have been well established: increased iron intake or elevated ferritin levels are individual risk factors for diabetes, metabolic syndrome or gestational diabetes. When in presence of dysmetabolic hyperferritinemia, a small number of randomized controlled trials have suggested that therapeutic measures aimed at reducing ferritin levels such as low red meat consumption, deferoxamin or therapeutic phlebotomies have shown a beneficial effect on glucose homeostasis, lipid profile and impaired hepatic markers observed in non-alcoholic steatohepatitis.
authors: Service de médecine interne, Département de médecine, CHUV, Lausanne. gerad.waeber@chuv.ch
authors: G
authors: G
authors: Waeber
authors: P
authors: P
authors: Vollenweider
authors: P-M
authors: PM
authors: Marques-Vidal
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D005234:Fatty Liver / Q000503:physiopathology / Q000628:therapy; D005293:Ferritins / Q000097:blood*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008659:Metabolic Diseases / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D065626:Non-alcoholic Fatty Liver Disease; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D008055:Lipids; D005293:Ferritins; D005947:Glucose